1. CLINICAL AND BIOLOGICAL EVALUATION OF THE NOVEL CD30/CD16A TETRAVALENT BISPECIFIC ANTIBODY (AFM13) IN RELAPSED OR REFRACTORY CD30‐POSITIVE LYMPHOMA WITH CUTANEOUS PRESENTATION: A BIOMARKER PHASE IB/IIA STUDY (NCT03192202). (12th June 2019) Authors: Sawas, A.; Chen, P.; Vlad, G.; Lipschitz, M.; Abdul‐Hay, M.; Lue, J.; Deng, C.; Amengual, J.E.; Marchi, E.; Shulman, J.; Elgedawe, H.; Shong, M.V.; Khan, K.; Geskin, L.; Rodig, S.J.; O'Connor, O. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗